A2846

A-134974 dihydrochloride hydrate

≥98% (HPLC), solid

• Sinónimos: N⁷-[(1′R,2′S,3′R,4′S)-2′,3′-dihydroxy-4′-aminocyclopentyl]-4-amino-5-iodopyrrolopyrimidine dihydrochloride hydrate
• Fórmula empírica (notación de Hill): C₁₁H₁₄IN₅O₂ · 2HCl · xH₂O
• Número CAS: 1049737-44-1
• Peso molecular: 448.09 (anhydrous basis)
• NACRES: NA.77
• PubChem Substance ID: 24890697
• UNSPSC Code: 12352200
• MDL number: MFCD08692561
• Assay: ≥98% (HPLC)
• Form: solid
• Storage condition: desiccated

Propiedades

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: solid
• storage condition: desiccated
• color: off-white to light tan
• solubility: H₂O: soluble
• originator: Abbott
• SMILES string: O.Cl.Cl.N[C@H]1C[C@H]([C@H](O)[C@@H]1O)n2cc(I)c3c(N)ncnc23
• InChI: 1S/C11H14IN5O2.2ClH.H2O/c12-4-2-17(6-1-5(13)8(18)9(6)19)11-7(4)10(14)15-3-16-11;;;/h2-3,5-6,8-9,18-19H,1,13H2,(H2,14,15,16);2*1H;1H2/t5-,6+,8+,9-;;;/m0.../s1
• InChI key: INMLNTBMPNIKQK-HWZUHWJPSA-N

Descripción

Biochem/physiol Actions

A-134974 is a novel and selective adenosine kinase (AK) inhibitor with IC₅₀ = 60 pM. Systemic A-134974 (i.p.) dose dependently reduced hyperalgesia (ED₅₀= 1 μmol/kg) and at higher doses, reduced locomotor activity (ED₅₀ = 16 μmol/kg). Administration of A-134974 intrathecally (i.t.) was more potent (ED₅₀= 6 nmol) at producing antihyperalgesia than delivering the compound by intracerebralventricular (ED₅₀ = 100 nmol, i.c.v.) or intraplantar (ED₅₀ >300 nmol) routes. In contrast, i.c.v. administration of A-134974 was more effective in reducing locomotor activity than i.t. administration (ED₅₀ values were 1 and >100 nmol, respectively). Increasing the pretreatment time for i.t.-delivered A-134974 caused a greater reduction in locomotor activity (ED₅₀= 10 nmol). This was due to diffusion of A-134974 (i.t.) to supraspinal sites. These data demonstrate that the novel AK inhibitor A-134974 potently reduces thermal hyperalgesia primarily through interactions with spinal sites, whereas its ability to depress locomotor activity is predominantly mediated by supraspinal sites.

A-134974 is a novel and selective adenosine kinase inhibitor. In a rat model of neuropathic pain, intraperitoneal A-134974 reduced tactile allodynia and hyperalgesia in a dose-dependent manner (IC₅₀ = 60 pM).

Features and Benefits

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold under license from Abbott Laboratories.

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)